Ysios Capital has supplied a series A extension that follows an initial tranche co-led by Kurma Partners and Sunstone Life Science Ventures in November 2020.
Synendos Therapeutics, a Switzerland-based spinout of University of Bern focused on central nervous system disorders, has raised additional series A financing to bring the round’s total to CHF24m ($26.4m).
Ysios Capital supplied the extension after Kurma Partners and Sunstone Life Science Ventures had provided an initial $21.9m tranche in November last year.
Founded in 2019, Synendos is working on inhibitors for a newly identified target in the body’s endocannabinoid system, a key neuromodulator system in the central…
